EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company's ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. EXACT Therapeutics AS has a collaboration with GE Healthcare for the development of a ready-to-use formulation of Sonazoid for ultrasound imaging and therapy; and with Agenus Inc. to develop proprietary immune checkpoint inhibitors in combination with EXACT's Acoustic Cluster Technology, in pancreatic cancer. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.